All Issue

2021 Vol.51, Issue 3 Preview Page

Review Article

September 2021. pp. 103-111
Abstract
References
1

Wang L, Verschuuren EAM, van Leer-Buter CC, Bakker SJL, de Joode AAE, Westra J, et al. Herpes zoster and immunogenicity and safety of zoster vaccines in transplant patients: A narrative review of the literature. Front Immunol 2018;9:1632.

10.3389/fimmu.2018.0163230079064PMC6062765
2

Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 2012;24: 494-500.

10.1016/j.coi.2012.06.00222857823
3

van der Heiden M, de Rond LGH, van Zelm MC, Berbers GAM, Boots AMH, Buisman AM. Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults. Front Immunol 2018;9:46.

10.3389/fimmu.2018.0004629410671PMC5787056
4

Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines 2014;2:39-55.

10.1177/205101361351562124757524PMC3991154
5

Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014;12:197-210.

10.1038/nrmicro321524509782PMC4066823
6

Peters GA, Tyler SD, Grose C, Severini A, Gray MJ, Upton C, et al. A Full-Genome Phylogenetic Analysis of Varicella-Zoster Virus Reveals a Novel Origin of Replication-Based Genotyping Scheme and Evidence of Recombination between Major Circulating Clades. J Virol 2006;80:9850-60.

10.1128/JVI.00715-0616973589PMC1617253
7

Al-Anazi KA, Al-Anazi WK, Al-Jasser AM. The beneficial effects of varicella zoster virus. J Hematol Clin Res 2019;3:16-49.

10.29328/journal.jhcr.1001010
8

Arvin AM. Varicella-Zoster Virus. Clin Microbiol Rev 1996;9:361-81.

10.1128/CMR.9.3.3618809466PMC172899
9

Vafai A. Varicella-Zoster Virus Subunit Vaccine. The Open Vaccine Journal 2009;2:17-27.

10.2174/1875035400902010017
10

Olson JK, Santos RA, Grose C. Varicella-zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. J Infect Dis 1998;178:S2-6.

10.1086/5142559852964
11

Oliver SL, Yang E, Arvin AM. Varicella-Zoster virus glycoproteins: Entry, Replication, and Pathogenesis. Curr Clin Microbiol Rep 2016;3:204-15.

10.1007/s40588-016-0044-428367398PMC5373811
12

Warren-Gash C, Forbes H, Breuer J. Varicella and herpes zoster vaccine development: lessons learned. Expert Rev Vaccines 2017;16:2291-201.

10.1080/14760584.2017.139484329047317PMC5942150
13

Pasquale AD, Preiss S, Silva FTD, Garçon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines 2015;16:320-43.

10.3390/vaccines302032026343190PMC4494348
14

Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicella-zoster virus retains major histocompatibility complex class I proteins in the golgi compartment of infected cells. J Virol 2001;75:4878-88.

10.1128/JVI.75.10.4878-4888.200111312359PMC114242
15

Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella-zoster virus infection. Nat Rev Dis Primers 2015;1:15016.

10.1038/nrdp.2015.1627188665PMC5381807
16

Abendroth A, Kinchington PR, Slobedman B. Varicella zoser virus immune evasion strategies. Curr Top Microbiol Immunol 2010;324:155-71.

10.1007/82_2010_4120563710PMC3936337
17

Arvin AM. Humoral and Cellular Immunity to Varicella-Zoster Virus: An Overview. J Infect Dis 2008;197:S58-60.

10.1086/52212318419410
18

Gerade C, Campbell TM, Kennedy JJ, McSharry BP, Steain M, Slobedman B, et al. Manipulation of the innate immune response by varicella zoster virus. Front Immunol 2020;11:1.

10.3389/fimmu.2020.0000132038653PMC6992605
19

Sironi M, Peri AM, Cagliani R, Forni D, Riva S, Biasin M, et al. TLR3 Mutations in Adult Patients With Herpes Simplex Virus and Varicella-Zoster Virus Encephalitis. J Infect Dis 2017;215:1430-4.

10.1093/infdis/jix16628368532
20

Laing KJ, Ouwendijk WJD, Koelle DM, Verjans GMGM. Immunobiology of Varicella-Zoster virus infection. J infect Dis 2018;218:S68-74.

10.1093/infdis/jiy40330247598PMC6151075
21

Schönrich G, Raftery MJ. Dendritic cells as Achilles' heel and Trojan horse during varicella zoster virus infection. Front Microbiol 2015;6:417.

10.3389/fmicb.2015.0041726005438PMC4424880
22

Sadaoka K, Okamoto S, Gomi Y, Ishikawa T, Yoshikawa T, Asano Y, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 2008;198:1327-33.

10.1086/59221918774884
23

Steain M, Sutherland JP, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol 2014;88:2704-16.

10.1128/JVI.03445-1324352459PMC3958057
24

Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker JA, et al. Varicella-Zoster Virus-specific cellular immune response to the live attenuated zoster vaccine in young and older adults. J Immunol 2017;199:604-12.

10.4049/jimmunol.170029028607114PMC5505810
25

Sei JJ, Cox KS, Dubey SA, Antonello JM, Krah DL, Casimiro DR, et al. Effector and central memory poly-functional CD4(+) and CD8(+) T cells are boosted upon ZOSTAVAX(®) vaccination. Front Immunol 2015;6:553.

10.3389/fimmu.2015.0055326579128PMC4629102
26

Arvin A, Abendroth A. VZV: immunobiology and host response. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge University Press; 2007. chapter 39.

27

Weinberg A, Levin MJ. VZV T-cell mediated immunity. Curr Top Microbiol Immunol 2010;342:341-57.

10.1007/82_2010_3120473790
28

Yu HR, Chen RF, Hong KC, Bong CN, Lee WI, Kuo HC, et al. IL-12 independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus. Eur J Immunol 2005;35:3664-72.

10.1002/eji.20052625816285008
29

Torigo S, Ihara T, Kamiya H. IL-12, IFN-r, and TNF-α released from mononuclear cells inhibit the spread of varicella- zoster virus at an early stage of varicella. Microbiol Immunol 2000;44:1027-31.

10.1111/j.1348-0421.2000.tb02599.x11220676
30

Zajkowska A, Garkowski A, Świerzbińska R, Kułakowska A, Król ME, Ptaszyńska-Sarosiek I, et al. Evaluation of chosen cytokine levels among patients with herpes zoster as ability to provide immune response. PLoS One 2016;11:e0150301.

10.1371/journal.pone.015030126934574PMC4775057
31

Jenkins DE, Redman RL, Lam EM, Liu C, Lin I, Arvin AM. Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J infect Dis 1998;178:940-8.

10.1086/5157029806019
32

Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J infect Dis 2003;188:40-52.

10.1086/37582812825169
33

Ogunjimi B, Smits E, Heynderickx S, Van den Bergh J, Bilcke J, Jansens H, et al. Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians. Clin Vaccine Immunol 2014;21:417-26.

10.1128/CVI.00818-1324429070PMC3957663
34

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-Zoster Virus-Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. J infect Dis 2008;197:825-35.

10.1086/52869618419349PMC4014857
35

Weinberg A, Pang L, Johnson MJ, Caldas Y, Cho A, Tovar-Salazar A, et al. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. J Virol 2019;93:e00305-19.

10.1128/JVI.00305-19
36

Gabutti G, Bolognesi N, Sandri F, Florescu C, Stefanati A. Varicella zoster virus vaccines: an update. ImmunoTargets Ther 2019;8:15-28.

10.2147/ITT.S17638331497569PMC6689529
37

Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother 2019;15:772-7.

10.1080/21645515.2018.156091830676834PMC6605864
38

Sadaoka T, Mori Y. Vaccine Development for Varicella-Zoster Virus. Adv Exp Med Biol 2018;1045:123-42.

10.1007/978-981-10-7230-7_729896666
39

Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther 2016;16:265-71.

10.1517/14712598.2016.113448126865048
40

Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012;30:3126-35.

10.1016/j.vaccine.2012.01.08822326899
41

Levin MJ, Weinberg A. Adjuvanted recombinant glycoprotein E herpes zoster vaccine. Clin Infect Dis 2020;70:1509-15.

10.1093/cid/ciz77031618437
42

Gershon AA. Tale of two vaccines: differences in response to herpes zoster vaccines. J Clin Invest 2018;128:4245-7.

10.1172/JCI12321730179221PMC6159952
43

Brosio F, Masetti G, Matteo G, Stefanati A, Gabutti G. A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile. Infect Drug Resist 2018;11:1401-11.

10.2147/IDR.S14830330233219PMC6130298
44

Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, et al. Comparative Immune Responses to Licensed Herpes Zoster Vaccines. J Infect Dis 2018;218:S81-7.

10.1093/infdis/jiy38330247596
45

Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 2013;138:779-95.

46

O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001;1:273-86.

10.2174/156800501460600812455401
47

Bonam SR, Partidos CD, Halmuthur SKM, Muller S. An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy. Trends Pharmacol Sci 2017;38:771-93.

10.1016/j.tips.2017.06.00228668223
48

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008;26:1375-86.

10.1016/j.vaccine.2007.12.03818272264
49

Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010;28:C25-36.

10.1016/j.vaccine.2010.07.02120713254
50

Harini PA, Kumar HGA, Kumar GP, Neeta S. An Overview of Immunologic Adjuvants - A Review. J Vaccines Vaccin 2013;4:1-4.

51

Vasou A, Sultanoglu N, Goodbourn S, Randall RE, Kostrikis LG. Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses. Viruses 2017;9:186.

10.3390/v907018628703784PMC5537678
52

Arnold N, Messaoudi I. Herpes zoster and the search for an effective vaccine. Clin Exp Immunol 2017;187:82-92.

10.1111/cei.1280927164323PMC5167054
Information
  • Publisher :The Korean Society for Microbiology
  • Publisher(Ko) :대한미생물학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 51
  • No :3
  • Pages :103-111
  • Received Date :2021. 08. 23
  • Revised Date :2021. 09. 17
  • Accepted Date : 2021. 09. 23